Cullinan Therapeutics explores B cell depletion in novel autoimmune treatments

Cullinan Therapeutics explores B cell depletion in novel autoimmune treatments
Cullinan Therapeutics targets autoimmune causes

Cullinan Therapeutics is exploring innovative T cell engager therapies aimed at depleting disease-causing B cells, presenting a new approach to treating autoimmune diseases by addressing their root causes.

Professor Grieshaber-Bouyer, MD, PhD, offers further insights into how this strategy may represent a shift in addressing autoimmunity, emphasizing the potential for disease-altering treatments. Details of this emerging therapy were discussed in the context of the EULAR2026 event.

Cullinan Therapeutics recently released its Q1 2026 financial results along with updates on its pipeline and development milestones. The company is also set to present initial clinical data for its CD19 and BCMA T cell engager therapies for autoimmune diseases on June 10. These efforts reflect Cullinan’s continued focus on advancing therapeutic candidates in autoimmunity.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.